State Street SPDR S&P Pharmaceuticals ETF
XPH
61 hedge funds and large institutions have $154M invested in State Street SPDR S&P Pharmaceuticals ETF in 2019 Q2 according to their latest regulatory filings, with 7 funds opening new positions, 11 increasing their positions, 27 reducing their positions, and 24 closing their positions.
2.81% less ownership
Funds ownership: 74.66% → 71.85% (-2.8%)
16% less capital invested
Capital invested by funds: $185M → $154M (-$30.3M)
24% less funds holding
Funds holding: 80 → 61 (-19)
59% less repeat investments, than reductions
Existing positions increased: 11 | Existing positions reduced: 27
71% less first-time investments, than exits
New positions opened: 7 | Existing positions closed: 24
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
JP Morgan Chase
New York
|
+$9.83M |
| 2 |
Susquehanna International Group
Bala Cynwyd,
Pennsylvania
|
+$1.2M |
| 3 |
Citadel Advisors
Miami,
Florida
|
+$697K |
| 4 |
D.E. Shaw & Co
New York
|
+$665K |
| 5 |
PNC Financial Services Group
Pittsburgh,
Pennsylvania
|
+$489K |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Morgan Stanley
New York
|
-$12.3M |
| 2 |
Barclays
London,
United Kingdom
|
-$5.9M |
| 3 |
CS
Credit Suisse
Zurich,
Switzerland
|
-$4.65M |
| 4 |
CI
Cavalier Investments
Alpharetta,
Georgia
|
-$2.3M |
| 5 |
RJA
Raymond James & Associates
St Petersburg,
Florida
|
-$1.61M |
XPH Hedge Fund Activity: Q2 2019 in Review
61 of the 4,604 institutional investors tracked by Wall St. Rank reported a position in State Street SPDR S&P Pharmaceuticals ETF (XPH) for Q2 2019, worth a combined $154M — down 16% from $185M a quarter earlier.
Sellers outnumbered buyers: 24 funds closed out of XPH and 7 opened new positions — a net loss of 17 holders — while 27 trimmed existing stakes and 11 added.
The largest buyer was JP Morgan Chase, adding an estimated $9.83M. The largest seller was Morgan Stanley, cutting an estimated $12.3M.
- 61 institutional investors held State Street SPDR S&P Pharmaceuticals ETF (XPH) as of Q2 2019, down from 80 in Q1 2019.
- Funds reported $154M of State Street SPDR S&P Pharmaceuticals ETF stock for Q2 2019, down 16% quarter-over-quarter.
- 7 funds opened new State Street SPDR S&P Pharmaceuticals ETF positions in Q2 2019 and 24 closed out, a net change of -17 holders.
- The largest State Street SPDR S&P Pharmaceuticals ETF buyer in Q2 2019 was JP Morgan Chase, an estimated $9.83M added.
- The largest State Street SPDR S&P Pharmaceuticals ETF seller in Q2 2019 was Morgan Stanley, an estimated $12.3M sold.
Based on aggregated 13F filings for Q2 2019.